TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00025259

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-Field Radiation Therapy
Description: Undergo IFRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-Field Radiation Therapy
Description: Undergo IFRT
Study: NCT02743871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06817024
Description: Subjects will be given two doses of PF-06817024 intravenously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for PF-06817024
Description: Subjects will be given two doses of PF-06817024 intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06817024
Description: Subjects will be given 2 doses intravenously
Study: NCT02985892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SSASG
Description: Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization active stretching group (SSASG) will perform stretch exercises in four sets of 30 seconds for each muscle. The active stretching exercises will last 15 minutes. The muscles that will be stretched are pectorals, latissimus dorsi, latissimus dorsi, teres major, rectus abdominis, external and internal oblique.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SSPSG
Description: Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization placebo stretching group (SSPSG) will perform exercises that simulate stretching, but the muscles will not suffer effective stretch. The placebo stretching exercises will last 15 minutes. The muscles that will be stretched are wrist flexors and extensors muscles and fingers flexors and extensors muscles.
Study: NCT00025259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally
Study: NCT00391469

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Rapid infusion of 2 liters of 4oC normal saline
Description: Patients randomized to mild hypothermia will receive a rapid infusion of 2 liters of 4oC normal saline prior to arrival in the emergency room. Patients randomized to control will receive standard of care following resuscitation from cardiac arrest.
Study: NCT00025259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally
Study: NCT00391469

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Rapid infusion of cold normal saline
Study: NCT03073018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosinopril
Description: oral administration, capsules
Study: NCT02743871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06817024
Description: Subjects will be given 2 doses intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06817024
Description: Subjects will be given 2 doses intravenously
Study: NCT03073018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosinopril
Description: oral administration, capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: oral administration, capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: oral administration, capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fosinopril Placebo
Description: oral administration, capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosinopril Placebo
Description: oral administration, capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pravastatin Placebo
Description: oral administration, capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin Placebo
Description: oral administration, capsules
Study: NCT01693874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Mindfulness-Based Stress Reduction

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control (health education)
Description: health education
Study: NCT01636505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ghrh antagonist (cetrotide/orgalutran)
Description: cetrotide/orgalutran 0.25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gnrh agonist (suprefact)
Description: suprefact 5.5 ml
Study: NCT00532740

Intervention type: RADIATION
Intervention: Yttrium Y 90 glass microspheres
Description: Between 0.2 to 0.5 Curies (200-500-mCi), either single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart per treating physician's discretion.
Study: NCT01384630

Intervention type: DRUG
Group type: OTHER
Intervention: RA-18C3
Description: 200 mg subcutaneous injection
Study: NCT02330302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ultrasound-guided femoral nerve block with Ropivacaine 0.5% 30mls

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ultrasound-guided suprainguinal approach to fascia iliaca block with Ropivacaine 0.5% 30mls
Study: NCT02310230

Intervention type: DEVICE
Group type: OTHER
Intervention: ExSpiron Respiratory Variation Monitor
Description: Non-invasive monitoring of minute ventilation, tidal volume, and respiratory rate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExSpiron Respiratory Variation Monitor
Description: Non-invasive monitoring of minute ventilation, tidal volume, and respiratory rate.
Study: NCT02055261

Intervention type: DEVICE
Group type: OTHER
Intervention: Low frequency DBS of the pedunculopontine nucleus
Study: NCT02743871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for PF-06817024
Description: Subjects will be given 2 doses intravenously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for PF-06817024
Description: Subjects will be given 2 doses intravenously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for PF-06817024
Description: Subjects will be given 2 doses intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06817024
Description: Subjects will be given doses of PF-06817024 intravenously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for PF-06817024
Description: Subjects will be given doses of Placebo intravenously
Study: NCT03626623

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cytal Wound Matrix 1-Layer
Description: Cytal® Wound Matrix 1-Layer is composed of a porcine (pig) derived extracellular matrix known as urinary bladder matrix. It is intended for the management of a variety of wounds.The individual device is intended for one time use.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds. SOC associated procedures and policies may vary across clinical settings.
Study: NCT02856230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ranger SL DEB
Description: BTK angioplasty using Ranger SL DEB
Study: NCT01885143

Intervention type: RADIATION
Intervention: Digital Breast Tomosynthesis

Intervention type: RADIATION
Intervention: Digital Breast Tomosynthesis
Study: NCT00725023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDP© Lamp
Description: TDP© heat lamp is an electrical device with a heating element sitting behind a ceramic plate made of clay and minerals

Intervention type: DEVICE
Group type: OTHER
Intervention: Dummy TDP© Lamp
Description: The dummy TDP© heat lamp is an electrical device with the heating element removed.
Study: NCT04061915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infographic Intervention
Description: The intervention consists of participants viewing an HIV self-testing infographic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paper-based HIV self-testing information
Description: The control arm will read paper-based HIV self-testing instructions.
Study: NCT02563275

Intervention type: OTHER
Group type: OTHER
Intervention: motion analysis system

Intervention type: OTHER
Group type: OTHER
Intervention: parabolic flight
Study: NCT01322360

Intervention type: DRUG
Group type: OTHER
Intervention: Morphine Sulfate
Study: NCT04019665

Intervention type: OTHER
Group type: OTHER
Intervention: MMSE (mini mental state examination)
Description: mini mental state examination takes place during the consultation. The consultation is a general or post-emergency geriatric consultation.

Intervention type: OTHER
Group type: OTHER
Intervention: SAGE (Self-Administered Gerocognitive Exam)
Description: SAGE test contains a series of questions that assess the cognitive functioning. Sage was developed by the Ohio State University Wexner Medical Center. it's an online, at-home, self-screening dementia tool that has been scientifically evaluated, and it's demonstrated good results in accurately identifying cognitive deficits.
Study: NCT04111484

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adrenomedullin
Description: Adrenomedullin is a naturally found in the human body and has strong vasoactive properties.
Study: NCT00884039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anecortave acetate
Description: anterior juxtascleral depot of 15 mg anecortave acetate
Study: NCT00025259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given IV
Study: NCT03889080

Intervention type: DIAGNOSTIC_TEST
Intervention: functional MRI
Description: functional MRI scan of the brain

Intervention type: DIAGNOSTIC_TEST
Intervention: functional MRI
Description: functional MRI scan of the brain

Intervention type: DIAGNOSTIC_TEST
Intervention: functional MRI
Description: functional MRI scan of the brain
Study: NCT03451552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator
Description: Navigators will support patients to access community based resources for healthy living and self-management, rather than providing specific information about health issues. Navigators will teach patients how to identify available and relevant programs to meet their health-related goals, in their language of choice. The navigator will ensure that the individual understands the reason for referral and potential benefits. They will discuss social barriers potentially affecting patients' access to community health resources, and assist patients to prioritize their health goals and relevant resources to achieve these. The navigator will then assist patients to access the community-based services in the language of their choice to which they have been referred. The navigator may assist the patient in making appointments, coordinating transportation, and/or accompaniment to resources as required).
Study: NCT00884039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 mg anecortave acetate
Description: anterior juxtascleral depot of 30mg anecortave acetate
Study: NCT02182440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recAP
Description: One hour infusions once daily for three days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recAP
Description: One hour infusions once daily for three days
Study: NCT04134208

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET-CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT scan
Study: NCT03240016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg IV D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 100mg/m\^2 D1 and D8
Study: NCT04043156

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-precision RT
Description: 18 x 2.33 Gy of high-precision RT in 3.5 weeks
Study: NCT02838420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib
Description: Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
Study: NCT03452878

Intervention type: BEHAVIORAL
Intervention: Aggressive behavior
Description: Aggressive Behavior Scale, Quality of Life (SF-36) and Agitated Behavior Scale, measurement of thyroid-stimulating hormone (TSH), T4, T3, Cortisol, Luteinizing Hormone (LH), Estradiol, Prolactin, Progesterone, testosterone, and sex hormone-binding globulin (SHBG) and Resonance Magnetic Imaging.
Study: NCT04111484

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study: NCT02388945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APD
Description: PDGO APD machines used in the PD patients for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAPD
Description: CAPD used in the PD Patients for 8 weeks
Study: NCT01661439

Intervention type: DRUG
Intervention: low molecular weight heparin (enoxeparine)
Description: 1mg/kg enoxeparine SC daily from 1st day of the menstrual cycle and continue daily throughout the pregnancy after documentation of pregnancy,and stopped in absence of fetal cardiac activity.
Study: NCT02018328

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Study: NCT02356224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of SHR3824 taken for single dose.
Study: NCT02182440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recAP
Description: One hour infusions once daily for three days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 hour IV infusion once daily for 3 days
Study: NCT02356224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of SHR3824 taken for single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of SHR3824 taken for single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of SHR3824 taken for single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of SHR3824 taken for single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of SHR3824 taken for single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of SHR3824 taken for single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of Placebo taken for single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of Placebo taken for single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of Placebo taken for single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of Placebo taken for single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of Placebo taken for single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of Placebo taken for single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of Placebo taken for single dose.
Study: NCT03393546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auricular Point Acupressure
Description: It includes 4 weekly auricular point acupressure treatments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auricular Point Acupressure
Description: It includes 4 weekly auricular point acupressure treatments.
Study: NCT02525341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Description: A sequence of 8 - 10 core yoga poses, breathing and relaxation techniques were practiced in each yoga class, and 2 - 3 new poses were introduced progressively in each of the yoga session. Props such as blocks, blankets, belts, mats, and chairs were used during the session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic and strengthening exercises
Description: A 15 minute of gentle aerobic exercise and a 30 minute of strengthening program that includes both isometric (without moving the joints) and isotonic (moving the joints) exercises of the lower extremities were taught to the participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General education
Description: One-time Arthritis Foundation educational brochures focusing on the disease process, diet and exercise and OA management education were given.
Study: NCT01879332

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 3000 mg once daily
Description: Eslicarbazepine acetate 600 mg tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 3600 mg once daily
Description: Eslicarbazepine acetate 600 mg tablets for oral administration
Study: NCT03181568

Intervention type: DEVICE
Group type: OTHER
Intervention: MolecuLight i:X™ Imaging Device
Description: Offers real-time detection of important biological and molecular information of a wound. The MolecuLight i:X Imaging Device is intended to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device can capture and document either an image or video of the wound where the presence of fluorescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wound care
Description: Standard wound care of chronic wounds e.g. sampling, debridement, infection control
Study: NCT01849380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1(SuLi, QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively),
Study: NCT03194321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Extended-Release Oral Capsule
Description: Maintenance immunosuppression will consist of tacrolimus extended-release, mycophenolate mofetil 500mg twice daily or mycophenolate sodium 360mg twice daily, and prednisone.
Study: NCT00483223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given intravenously on the first day of each 3-week treatment cycle at 75mg/m2. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given intravenously on the first day of each 3-week treatment cycle at AUC 6. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
Study: NCT01085591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-183,315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-183,315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study: NCT01497132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Oral drops 30000 IU weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT00118365

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eflornithine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulindac
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04981951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Highly selective α2-adrenergic receptor agonist. With sedative, analgesic, peri-operative sympatholytic and hemodynamic stabilizing properties.